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ABSTRACT 
The M2 isoform of pyruvate kinase, highly expressed in tumor cells, is known to engage a 
feed forward loop with the glycolysis master transcription factor HIF-1. Gao and co-authors 
recently showed that dimeric PKM2 localizes to the nucleus in highly proliferating cancer 
cells, where it regulates in vivo growth by acting as a protein kinase and directly activating 
STAT3. STAT3 is therefore a novel player of the PKM2/HIF-1αfeedback loop, since HIF-
induced PKM2 activates STAT3 that in turn induces HIF-1αexpression.  These findings have 
profound implications for understanding the complex connections between gene regulation, 
metabolism, survival and proliferation in cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEXT 
Pyruvate kinase (PK) catalyzes the penultimate step of glycolysis by transferring 
phosphate from phosphoenolpyruvate (PEP) to ADP to generate ATP and pyruvate, which 
can then be converted in either lactate or acetyl-CoA to enter the TCA cycle. Of the four 
known isoforms, PKM1 and PKM2derive from an alternative splicing of the same 
pkm2gene.1PKM2 is highly expressed in embryonal cells and in tumors, and its prevalent 
expression in cancer cells has been linked to lower O2 consumption and higher lactate 
secretion and glucose intake. The switch to the PKM2 isoform, observed in tumors of 
different origin,2, 3 was shown to be essential for both the ‘Warburg’ effect and proliferation 
of cancer cells.4, 5 
The main feature distinguishing PKM2 from the PKM1 isoform is the fact that its 
pyruvate kinase activity is subject to multiple layers of regulation. PKM2 can exist as a 
tetramer, which is enzymatically active, or as aninactive dimer. Interestingly, tumors show 
very high levels of dimeric PKM2, which in normal proliferating cells is in contrast mainly 
tetrameric.6 Multiple signals such as growth factors, oncogenes or reactive oxygen species 
(ROS)were shown to destabilize the tetrameric form via a number of mechanisms including 
tyrosine phosphorylation, association with tyrosine phosphopeptides or oxidation.7-9 In turn, 
decreased PKM2 activity correlates with increased proliferation. Although this can be partly 
explained bythe diversion of glucose metabolites from catabolic to anabolic processes10 and 
by the increased generation of anti-oxidant NADPH via the pentose phosphate pathway,9 a 
consistent body of data points towards an independent role for PKM2 in the nucleus. Indeed, 
it was shown that both IL-3 and EGFR can induce PKM2 nuclear localization, correlating 
with cell proliferation.11, 12 Nuclear PKM2 can associate with cSrc-phosphorylated beta-
catenin, and bind to the ccnd1 gene promoter activating cyclin D1 transcription.12 Finally, 
PKM2 was recently proposed to be part of a “feed forward loop” enhancing the activity of 
hypoxia-inducible factor (HIF)-1, a key transcriptional regulator of both aerobic and 
anaerobic glycolysis.13 Indeed, HIF-1 can activate pkm2 gene transcription, and PKM2 in 
turn interacts with the HIF-1α subunit and promotes trans-activation of HIF-1 target genes, 
thus enhancing cellular responses to oxygen deprivation or oncogene activation.  
To investigate the functional significance of nuclear PKM2, Gao et al.14 have 
compared PKM2 nuclear localization in different cancer cell lines characterized by 
differential proliferative ability. Interestingly, they observed a strong correlation between 
PKM2nuclear levels, cell proliferation and mek5 gene transcription. Upon showing by ChIP 
analysis that PKM2 associates to the mek5 promoter, they went on demonstrating that nuclear 
PKM2 interacts with the transcription factor STAT3 and is able to directly trigger its 
activation via phosphorylation on tyrosine 705. The authors were also able to demonstrate 
that mek5 is a direct STAT3 transcriptional target, and that the levels of dimeric PKM2 
directly correlate with STAT3-mediated mek5 transcription, cell proliferation and in vivo 
growth of tumor cells. Interestingly, PKM2-mediated STAT3 tyrosine phosphorylation can 
be accomplished in vitro exclusively by dimeric PKM2, which uses PEP as a phosphate 
donor and likely interacts with its substrate via the ADP binding domain. Incidentally, the 
reaction will lead to pyruvate production via a yet alternative pathway. 
STAT3 is a point of convergence for many oncogenic signals, and its aberrant  
constitutive activity is crucial for the survival, proliferation and metastatic activity of tumors 
of different origin.15 Moreover, STAT3 constitutive activity plays a key role in inflammation-
induced cancer, by instating a feed forward loop entailing continuous production of the pro-
inflammatory cytokine IL-6 and constitutive NF-kB activation.16 We have recently shown 
that constitutively active STAT3 induces chronically enhanced hif-1αtranscription that results 
in increased HIF-1α protein levels and triggers a metabolic switch towards aerobic glycolysis 
similar to the Warburg effect.17, 18 
STAT3 activation appears thus toparticipate in the recently proposed PKM2/HIF-1α 
positive feedback loop,13 where oxygen deprivation or oncogenes lead to increased HIF-1α 
levels, HIF-1 induces pkm2 transcription, PKM2 enhances HIF-1 trans-activating power and 
activates STAT3, and finally activated STAT3 enhances HIF-1α expression (Figure 1). On 
the other hand, we have recently shown that constitutively active STAT3 can act as a first hit 
during the process of malignant transformation.19 Aberrantly continuous STAT3 activation 
like that found in chronic inflammation might therefore sensitize cells to tumor 
transformation by initiating the above described positive feedback loop, leading to enhanced 
HIF-1α and PKM2 expression/activity. This would in turn support aerobic glycolysis, 
anabolic cell metabolism, cell survival and proliferation. Moreover, PKM2-mediated STAT3 
phosphorylation may participate in the chronic STAT3 activation observed in highly 
glycolytic tumors of different origins.  Although these findings shed some light on the 
correlation between the tetrameric:dimeric PKM2 ratio, its nuclear activities and enhanced 
cell proliferation, several questions still remain unanswered. For example, why does PKM2 
preferentially localize in the nucleus in more proliferating cells? Is this a special feature of 
cancer cells? What is the mechanism that drives dimeric PKM2 to the nucleus? An intriguing 
possibility, adding one more layer of cross-talk, would be that the transcription factors/co-
factors known to interact with PKM2, i.e. beta-catenin, HIF-1α or STAT3, may mediate its 
transport to the nucleus. Another interesting implication of the findings by Gao et al. is the 
idea that STAT3 phosphorylation may take place in the nucleus, opposed to its canonical 
cytoplasmic activation pathway. This correlates with datasets showing that unphosphorylated 
STAT3 is continuously shuttling between the cytoplasm and the nucleus generating a 
reservoir of nuclear unphosphorylated STAT3 available for activation.20Additionally, the 
symultaneous detection of both PKM2 and STAT3 on the mek5 promoter suggests that 
nuclear phosphorylation of STAT3 by PKM2 might even occur on the DNA, similar to what 
has been recently shown for STAT3 serine phosphorylation.21 
Small molecules enhancing PKM2 tetrameric activity have already been proposed as 
new therapeutic tools to compromise both the anabolic and the anti-oxidant functions of this 
protein.9 The same compounds may also lead to the inhibition of PKM2-mediated STAT3 
activation, potentially representing a useful therapeutic tool to help hitting the uncontrolled 
growth of those highly glycolytic tumors that display both STAT3 activation and dimeric 
PKM2. 
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FIGURE LEGEND 
STAT3/PKM2/HIF-1α feed forward loop. Oxygen deprivation, growth factors or 
oncogenes lead to an increase in HIF-1α levels, HIF-1 induces pkm2 transcription, PKM2 
both enhances HIF-1 trans-activating power and activates STAT3, and activated 
STAT3induces HIF-1α expression. On the other hand, cytokines, growth factors or 
oncogenes activate STAT3 that can induce hif-1α transcription and start the positive feedback 
loop between STAT3, PKM2 and HIF-1α. However initiated, this leads to increased levels of 
proteins involved in glycolysis, enhancing the anaerobic-like metabolism known as Warburg 
effect. 
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